Founded in 2019, Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. Their technology focuses on a key molecular pathway that stimulates neurogenesis (the birth of new neurons) in the adult brain–one that has demonstrated proof of concept in mouse models.

This 2021 Brown Venture Prize Finalist was co-founded by Johnny Page ’24, Justin Fallon, Professor of Neuroscience, and Ashley Webb, Assistant Professor of Molecular and Cell Biology. The company received a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging in 2021.